Valmark Advisers Inc. Buys New Position in Cencora, Inc. (NYSE:COR)

Valmark Advisers Inc. purchased a new position in Cencora, Inc. (NYSE:COR - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,036 shares of the company's stock, valued at approximately $233,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of COR. Swedbank AB boosted its stake in shares of Cencora by 2.3% during the 3rd quarter. Swedbank AB now owns 1,394,449 shares of the company's stock valued at $313,863,000 after buying an additional 31,104 shares during the last quarter. Blue Trust Inc. boosted its stake in shares of Cencora by 108.7% during the 3rd quarter. Blue Trust Inc. now owns 2,776 shares of the company's stock valued at $625,000 after buying an additional 1,446 shares during the last quarter. Capital Investment Advisors LLC boosted its stake in shares of Cencora by 35.4% during the 3rd quarter. Capital Investment Advisors LLC now owns 1,334 shares of the company's stock valued at $300,000 after buying an additional 349 shares during the last quarter. Northwest Investment Counselors LLC purchased a new position in shares of Cencora during the 3rd quarter valued at approximately $70,000. Finally, Whittier Trust Co. boosted its stake in shares of Cencora by 1.0% during the 3rd quarter. Whittier Trust Co. now owns 7,812 shares of the company's stock valued at $1,758,000 after buying an additional 81 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company's stock.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 50,000 shares of the stock in a transaction on Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the completion of the transaction, the chairman now owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This represents a 13.28 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,678 shares of the stock in a transaction on Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the completion of the transaction, the executive vice president now directly owns 20,329 shares of the company's stock, valued at approximately $4,649,648.88. The trade was a 7.62 % decrease in their position. The disclosure for this sale can be found here. 10.80% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms have recently commented on COR. Evercore ISI increased their target price on Cencora from $270.00 to $280.00 and gave the company an "outperform" rating in a research note on Thursday, February 6th. Barclays upped their price target on Cencora from $263.00 to $290.00 and gave the company an "overweight" rating in a research report on Thursday, November 7th. Wells Fargo & Company upped their price target on Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research report on Wednesday, January 29th. Mizuho initiated coverage on Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target on the stock. Finally, UBS Group upped their price target on Cencora from $275.00 to $285.00 and gave the company a "buy" rating in a research report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $277.90.

Cencora Stock Performance

NYSE COR traded down $1.99 during trading hours on Friday, hitting $241.47. The company had a trading volume of 1,060,827 shares, compared to its average volume of 1,488,495. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. The business has a fifty day simple moving average of $239.34 and a 200-day simple moving average of $237.46. The firm has a market cap of $46.83 billion, a P/E ratio of 34.35, a price-to-earnings-growth ratio of 1.32 and a beta of 0.49.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. Equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be given a $0.55 dividend. This represents a $2.20 annualized dividend and a yield of 0.91%. The ex-dividend date of this dividend is Friday, February 14th. Cencora's dividend payout ratio is presently 31.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.